Journal Article Summary
The article investigates the effectiveness of methylnaltrexone (MNTX) in treating opioid-induced constipation (OIC) in hospitalized patients with advanced illnesses. OIC is a common and serious side effect of opioid medications, which can lead to severe complications such as fecal impaction and increased mortality. Given that many patients with advanced illnesses rely on opioids for pain management, addressing OIC is crucial for improving their quality of life and reducing healthcare burdens.
The study analyzed data from two clinical trials involving 364 patients who had advanced illnesses and were experiencing OIC despite using laxatives. Participants received either MNTX or a placebo, and the results showed that those treated with MNTX had significantly higher rates of achieving rescue-free laxation (RFL) within 4 and 24 hours after dosing compared to those receiving the placebo. The findings indicated that MNTX was effective regardless of the patients' functional status, and it did not negatively impact pain relief from opioids.
However, the study has limitations, including its post hoc nature and the differences in study designs. While MNTX was generally well tolerated, some patients experienced gastrointestinal side effects, which decreased over time. Patients and caregivers should discuss the use of MNTX with healthcare professionals, especially if they are dealing with OIC while on opioid therapy, to explore the potential benefits and any associated risks in their specific situations.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Farchadi David, Slatkin Neal E., Stambler Nancy, Israel Robert J., Matus Michael. Cumulative Laxation Response with Methylnaltrexone: Implications for Hospitalized Patients with Advanced Illness and Opioid-Induced Constipation. Current Therapeutic Research, Clinical and Experimental 2023. DOI: 10.1016/j.curtheres.2023.100694. PMID: 36875317. PMCID: PMC9981808.
Featured Pill Pals Product
Docusate Sodium /Senna 8.6-50 mg Tablets 100 Count --- Generic for Peri-Colace --- Rugby Pharma
Docusate Sodium /Senna 8.6-50 mg Tablets 100 Count --- Generic for Peri-Colace --- Rugby Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
